Your browser doesn't support javascript.
loading
Opening a Door to PARP Inhibitor-Induced Lethality in HR-Proficient Human Tumor Cells.
Hatchi, Elodie; Livingston, David M.
Affiliation
  • Hatchi E; Departments of Genetics and Medicine, Harvard Medical School, Department of Cancer Biology Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Livingston DM; Departments of Genetics and Medicine, Harvard Medical School, Department of Cancer Biology Dana-Farber Cancer Institute, Boston, MA 02115, USA. Electronic address: david_livingston@dfci.harvard.edu.
Cancer Cell ; 37(2): 139-140, 2020 02 10.
Article in En | MEDLINE | ID: mdl-32049041
ABSTRACT
PARP inhibition (PARPi) kills tumor cells defective in homologous recombination-based repair (HR-) but not their HR+ competent counterparts. In this issue of Cancer Cell, it is shown that, when EZH2 is functionally silenced, HR+, CARM1-high, high-grade serous ovarian cancer cells become PARPi sensitive, undergo mitotic catastrophe, and die.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Poly(ADP-ribose) Polymerase Inhibitors Limits: Female / Humans Language: En Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Poly(ADP-ribose) Polymerase Inhibitors Limits: Female / Humans Language: En Year: 2020 Type: Article